person · Reporting owner
GUIFFRE CHRISTOPHERD T
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dare Bioscience, Inc.CERU · Entity 7799 | Director · Chief Executive Officer | January 06, 2017 | January 09, 2017 |
| Pear Therapeutics, Inc.PEAR · Entity 114512 | CFO, COO, Treas., & Asst. Sec. | February 15, 2023 | February 17, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dare Bioscience, Inc.
Report date January 06, 2017 · Filed January 09, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2027-01-05 | Direct | 150,000 |
Reported balance
After 2017-01-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-06 · Grant · Acquired 150,000 · Balance 150,000 F1: This option was granted on January 6, 2017. The shares underlying the option are scheduled to vest in equal monthly installments over four years from January 1, 2017. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2027-01-05 | Direct | 150,000 |
Reported balance
After 2017-01-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-01-06 · Grant · Acquired 150,000 · Balance 150,000 F2: This option was granted on January 6, 2017. The option is scheduled to vest as to 25% of the shares on the six-month anniversary of January 1, 2017 and as to an additional 25% of the original number of shares at the end of each six-month period of continuous service thereafter until January 1, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on January 6, 2017. The shares underlying the option are scheduled to vest in equal monthly installments over four years from January 1, 2017.
F2: This option was granted on January 6, 2017. The option is scheduled to vest as to 25% of the shares on the six-month anniversary of January 1, 2017 and as to an additional 25% of the original number of shares at the end of each six-month period of continuous service thereafter until January 1, 2019.
Pear Therapeutics, Inc.
Report date February 15, 2023 · Filed February 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,285,714 |
Reported balance
After 2023-02-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-15 · Grant · Acquired 2,285,714 · Balance 2,285,714 F1: Each restricted stock unit represents a contingent right to receive one share of PEAR Class A Common Stock. F2: The restricted stock units shall vest and settle as to 33% on February 15, 2024; 33% on February 15, 2025; and 34% on February 15, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of PEAR Class A Common Stock.
F2: The restricted stock units shall vest and settle as to 33% on February 15, 2024; 33% on February 15, 2025; and 34% on February 15, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2023 Filed Feb 17, 2023 16:12 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | GrantRestricted Stock Units · Derivative | 2,285,714 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-004040 · form4.xml · derivative · entry 1 GUIFFRE CHRISTOPHERD T · CIK 0001219021 · CFO, COO, Treas., & Asst. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,285,714 Underlying: Class A Common Stock · 2,285,714 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of PEAR Class A Common Stock. F2 · derivative.exercise_date: The restricted stock units shall vest and settle as to 33% on February 15, 2024; 33% on February 15, 2025; and 34% on February 15, 2026. F2 · derivative.expiration_date: The restricted stock units shall vest and settle as to 33% on February 15, 2024; 33% on February 15, 2025; and 34% on February 15, 2026. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 16:07 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | SaleClass A Common Stock | 19,540 | $1.13 | $22,080.20 |
DisclosureSEC source: 0001062993-23-001325 · form4.xml · nonDerivative · entry 1 GUIFFRE CHRISTOPHERD T · CIK 0001219021 · CFO, COO, Treas., & Asst. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,960 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $1.03 to $1.335, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. Read SEC document |
| January 14, 2023 Filed Jan 18, 2023 17:03 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | Exercise / conversionRestricted Stock Units · Derivative | 49,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-001038 · form4.xml · derivative · entry 2 GUIFFRE CHRISTOPHERD T · CIK 0001219021 · CFO, COO, Treas., & Asst. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,500 Underlying: Common Stock · 49,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of PEAR common stock. F2 · derivative.exercise_date: The remaining restricted stock units shall vest and settle as to 33% of the shares on January 14, 2024 and 34% on January 14, 2025. F2 · derivative.expiration_date: The remaining restricted stock units shall vest and settle as to 33% of the shares on January 14, 2024 and 34% on January 14, 2025. Read SEC document |
| January 14, 2023 Filed Jan 18, 2023 17:03 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | Exercise / conversionCommon Stock | 49,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-001038 · form4.xml · nonDerivative · entry 1 GUIFFRE CHRISTOPHERD T · CIK 0001219021 · CFO, COO, Treas., & Asst. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 16:41 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | GrantRestricted Stock Units · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-004978 · form4.xml · derivative · entry 2 GUIFFRE CHRISTOPHERD T · CIK 0001219021 · CFO, COO, Treas., & Asst. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of PEAR common stock. F3 · derivative.exercise_date: The restricted stock units shall vest and settle as to 33% of the shares on January 14, 2023, 33% of the shares on January 14, 2024 and the final 34% on January 14, 2025. F3 · derivative.expiration_date: The restricted stock units shall vest and settle as to 33% of the shares on January 14, 2023, 33% of the shares on January 14, 2024 and the final 34% on January 14, 2025. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 16:41 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | GrantStock Option (Right to Buy) · Derivative | 118,170 | $0.00 Strike: $4.06 | $0.00 |
DisclosureSEC source: 0001062993-22-004978 · form4.xml · derivative · entry 1 GUIFFRE CHRISTOPHERD T · CIK 0001219021 · CFO, COO, Treas., & Asst. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,170 Underlying: Common Stock · 118,170 shares Expires 2032-02-16 F1 · derivative.exercise_date: 25% of the shares underlying the option shall vest on January 14, 2023 and an additional 2.0833 and 1/3% of the shares shall vest on the last day of each calendar month thereafter. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 17:24 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | GrantStock Option (Right to Buy) · Derivative | 228,224 | Not disclosed Strike: $1.29 | Not disclosed |
DisclosureSEC source: 0001062993-21-012391 · form4.xml · derivative · entry 5 GUIFFRE CHRISTOPHERD T · CIK 0001219021 · CFO, COO, Treas., & Asst. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,224 Underlying: Common Stock · 228,224 shares Expires 2031-01-26 F10 · price: Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 155,000 shares of common stock of Private Pear for $1.89 per share. F9 · derivative.exercise_date: 25% of the shares underlying the option vested or shall vest on January 26, 2022 and an additional 2.0833 and 1/3% of the shares vested or shall vest on the last day of each calendar month thereafter. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 17:24 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | GrantStock Option (Right to Buy) · Derivative | 242,948 | Not disclosed Strike: $1.09 | Not disclosed |
DisclosureSEC source: 0001062993-21-012391 · form4.xml · derivative · entry 4 GUIFFRE CHRISTOPHERD T · CIK 0001219021 · CFO, COO, Treas., & Asst. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,948 Underlying: Common Stock · 242,948 shares Expires 2030-03-24 F8 · price: Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 165,000 shares of common stock of Private Pear for $1.60 per share. F7 · derivative.exercise_date: 25% of the shares underlying the option vested or shall vest on March 24, 2021 and an additional 2.0833 and 1/3% of the shares vested or shall vest on the last day of each calendar month thereafter. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 17:24 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | GrantStock Option (Right to Buy) · Derivative | 103,068 | Not disclosed Strike: $1.08 | Not disclosed |
DisclosureSEC source: 0001062993-21-012391 · form4.xml · derivative · entry 3 GUIFFRE CHRISTOPHERD T · CIK 0001219021 · CFO, COO, Treas., & Asst. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,068 Underlying: Common Stock · 103,068 shares Expires 2029-03-14 F6 · price: Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 70,000 shares of common stock of Private Pear for $1.58 per share. F5 · derivative.exercise_date: 25% of the shares underlying the option vested or shall vest on March 14, 2020 and an additional 2.0833 and 1/3% of the shares vested or shall vest on the last day of each calendar month thereafter. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 17:24 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | GrantStock Option (Right to Buy) · Derivative | 51,533 | Not disclosed Strike: $0.72 | Not disclosed |
DisclosureSEC source: 0001062993-21-012391 · form4.xml · derivative · entry 2 GUIFFRE CHRISTOPHERD T · CIK 0001219021 · CFO, COO, Treas., & Asst. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,533 Underlying: Common Stock · 51,533 shares Expires 2028-03-21 F4 · price: Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 35,000 shares of common stock of Private Pear for $1.05 per share. F3 · derivative.exercise_date: 25% of the shares underlying the option vested or shall vest on December 7, 2018 and an additional 2.0833 and 1/3% of the shares vested or shall vest on the last day of each one month period thereafter. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 17:24 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | GrantStock Option (Right to Buy) · Derivative | 478,533 | Not disclosed Strike: $0.68 | Not disclosed |
DisclosureSEC source: 0001062993-21-012391 · form4.xml · derivative · entry 1 GUIFFRE CHRISTOPHERD T · CIK 0001219021 · CFO, COO, Treas., & Asst. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 478,533 Underlying: Common Stock · 478,533 shares Expires 2027-12-13 F2 · price: Received in accordance with the terms of the Business Combination Agreement (the "Business Combination Agreement") dated as of June 21, 2021, by and among Thimble Point Acquisition Corp., Oz Merger Sub, Inc. and Pear Therapeutics (US), Inc. (f/k/a Pear Therapeutics, Inc.) ("Private Pear"), in exchange for an option to acquire 325,000 shares of common stock of Private Pear for $1.00 per share. F1 · derivative.exercise_date: 25% of the shares underlying the option vested or shall vest on December 7, 2018 and an additional 2.0833 and 1/3% of the shares vested or shall vest on the last day of each one month period thereafter. Read SEC document |
| January 06, 2017 Filed Jan 9, 2017 22:13 UTC | Dare Bioscience, Inc. CERU · Entity 7799 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001209191-17-002978 · doc4.xml · derivative · entry 2 GUIFFRE CHRISTOPHERD T · CIK 0001219021 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-01-05 F2 · derivative.exercise_date: This option was granted on January 6, 2017. The option is scheduled to vest as to 25% of the shares on the six-month anniversary of January 1, 2017 and as to an additional 25% of the original number of shares at the end of each six-month period of continuous service thereafter until January 1, 2019. Read SEC document |
| January 06, 2017 Filed Jan 9, 2017 22:13 UTC | Dare Bioscience, Inc. CERU · Entity 7799 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001209191-17-002978 · doc4.xml · derivative · entry 1 GUIFFRE CHRISTOPHERD T · CIK 0001219021 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-01-05 F1 · derivative.exercise_date: This option was granted on January 6, 2017. The shares underlying the option are scheduled to vest in equal monthly installments over four years from January 1, 2017. Read SEC document |
| December 31, 2016 Filed Jan 5, 2017 21:21 UTC | Dare Bioscience, Inc. CERU · Entity 7799 | GrantCommon Stock | 5,733 | $0.60 | $3,439.80 |
DisclosureSEC source: 0001209191-17-002068 · doc4.xml · nonDerivative · entry 1 GUIFFRE CHRISTOPHERD T · CIK 0001219021 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,489 F1 · kind: These shares were acquired under the Cerulean Pharma Inc. Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.